The SUSTAIN and STEP trial programs, which established semaglutide's efficacy for diabetes management and weight loss respectively, did not identify specific safety concerns related to concomitant blood thinner use
Significantly more tirzepatide patients hit every major weight loss milestone, including 10%, 15%, 20%, and 25% body weight reduction
Before injecting, clean the area with an alcohol swab or soap and water
Can Stopping GLP-1 Treatment Early Be Harmful
The long-term effects of use are unknown, and the quality of products available outside of research settings may vary substantially
Is there a faster route that involves fewer stops